Lv4
420 积分 2021-07-12 加入
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial
2个月前
已完结
Developments in nanotechnology approaches for the treatment of solid tumors
2个月前
已完结
Small cell lung cancer
4个月前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
4个月前
已完结
Medical treatment for active breast cancer brain metastases
7个月前
已完结
3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)
8个月前
已关闭
The incredible journey: From megakaryocyte development to platelet formation
9个月前
已完结
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
9个月前
已完结
ALK in cancer: from function to therapeutic targeting
10个月前
已完结
Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
10个月前
已完结
皖公网安备34019202002308
